Amphetamine is a common therapeutic agent for alleviating the core symptoms associated with attention-deficit hyperactivity disorder (ADHD) in children and adults. The current study used a translational model of attention, the five-choice serial reaction time (5-CSRT) procedure with rats, to examine the time-course effects of d-amphetamine. Effects of different dosages of d-amphetamine were related to drug-plasma concentrations, fashioned after comprehensive pharmacokinetic/pharmacodynamic assessments that have been employed in clinical investigations. We sought to determine whether acute drug-plasma concentrations that enhance performance in the 5-CSRT procedure are similar to those found to be therapeutic in patients diagnosed with ADHD. Results from the pharmacokinetic/pharmacodynamic assessment indicate that d-amphetamine plasma concentrations associated with improved performance on the 5-CSRT procedure overlap with those that have been reported to be therapeutic in clinical trials. The current findings suggest that the 5-CSRT procedure may be a useful preclinical model for predicting the utility of novel ADHD therapeutics and their effective concentrations. Behavioural Pharmacology 29:551-556
Introduction
Psychostimulants are the mainstay of treatment for alleviating the behavioral symptoms of inattention, impulsivity, and hyperactivity associated with attention-deficit hyperactivity disorder (ADHD) (Childress and Tran, 2016; Bachmann et al., 2017; De Crescenzo et al., 2017) . Amphetamine treatment leads to clinically significant reductions in these symptoms in 55-70% of patients (Berman et al., 2009) . One research tool used to show the therapeutic effects of an ADHD pharmacotreatment is the continuous performance task (CPT). Although there are variants of the task (Riccio et al., 2001) , CPT typically assesses attention to an infrequently occurring stimulus, and psychostimulants have been proven successful in enhancing the detection of that stimulus.
In preclinical research, the five-choice serial reaction time (5-CSRT) procedure is a variant of the CPT that has been proposed as a model of attention and impulse control (Robbins, 2002) . Previous studies revealed that acute injections of d-amphetamine and methylphenidate can increase the percentage of correct responses in the 5-CSRT procedure (Grottick and Higgins, 2002; Bizarro et al., 2004; Paine et al., 2007; Navarra et al., 2008) , and that those effects can be enhanced under variations of the procedure, including intermittent (Koffarnus and Katz, 2011) and delayed reinforcement (Slezak and Katz, 2013) .
Although some studies have reported negligible effects of d-amphetamine and methylphenidate on 5-CSRT performance (Cole and Robbins, 1987; Puumala et al., 1996; Bizzaro and Stolerman, 2003; Paterson et al., 2011) , others have found that improved performance is selective for stimulant drugs, as compared with drugs from other classes (Paine et al., 2007; Koffarnus and Katz, 2011) , further suggesting the predictive validity of this procedure as a model for ADHD.
The present study determined the effects of d-amphetamine in the 5-CSRT procedure over time and related those effects to drug-plasma concentrations. Those results were further compared with the pharmacodynamic/pharmacokinetic analyses reported in clinical studies (Brown et al., 1979 (Brown et al., , 1980 Greenhill et al., 2003) . In particular, the study determined whether acute drug-plasma concentrations of d-amphetamine that enhanced performance in the 5-CSRT procedure overlap with therapeutic amphetamine plasma concentrations measured in clinical trials of patients diagnosed with ADHD. A potential similarity of plasma concentrations that improved performance in the 5-CSRT and those detected in clinical trials would support the use of the 5-CSRT procedure as a useful preclinical ADHD model for screening novel therapeutics.
Methods

Subjects
Six male Sprague-Dawley rats (Taconic Farms, Hudson, New York, USA) weighing 300-350 g served as subjects and were housed individually in a temperature-controlled and humidity-controlled environment under a 12-h light/ dark cycle. All rats were fed~10-15 g of standard rat chow 1 h after each session in their home cages where water was continuously available. Thus, each subject was 22-h food restricted before the start of each experimental session. Care of subjects was in accordance with the guidelines of the NIH and the NIDA IRP Animal Care and Use Program.
Five additional male Sprague-Dawley rats (Taconic Farms) weighing 300-350 g were used for the determination of plasma d-amphetamine concentrations. These animals were housed as described above with unrestricted access to water and food. Animal care and experimental manipulations were approved by the Institutional Animal Care and Use Committee at the Johns Hopkins University School of Medicine. Animal facilities at both Johns Hopkins and NIDA IRP are accredited by the AAALAC International.
Apparatus
Experimental sessions were conducted in operantconditioning chambers designed for the 5-CSRT procedure (MED-NP5L package; Med-Associates Inc., St. Albans, Vermont, USA). One wall of the chamber contained five horizontal square 2.5-cm openings, located 2 cm above the grid floor. The wall was curved so that each opening was 25 cm from the midpoint of the opposing wall. Each opening could be illuminated from behind with 3-W clear light-emitting diodes. The opposite wall was not curved and contained a food tray into which 45-mg food pellets could be delivered. A house light was located at the top of the wall above the food tray. The chambers were contained within lightproof, ventilated enclosures that provided sound attenuation. White noise was delivered to the chamber at all times to mask extraneous noise.
Procedure
5-Choice serial reaction time task
Sessions were conducted daily, Mondays through Fridays, and ended after 50 food presentations or 40 min, whichever occurred first (median session durations ranged from 6 to 12 min across subjects). Each trial started with an illumination of the house light and a sample stimulus light (initially for 30 s) behind one of the five apertures. A single response (nose poke) within the illuminated aperture was reinforced with a 45-mg food pellet (accompanied by illumination of the food-tray light and termination of the house light). An intertrial interval (ITI) followed food delivery, with the food-tray remaining illuminated for its duration, but without scheduled consequences for responses. If a response was not emitted within 30 s of the illumination of the sample stimulus ('limited hold' period), or if a response was emitted in an incorrect aperture, the trial was terminated and immediately followed by an ITI with the house light remaining illuminated, followed by the start of the next trial. Training started with 30-s stimulus durations, 2-s ITIs, and 30-s 'limited hold' periods. The stimulus duration and ITI were gradually altered over training sessions to the final parameters of 1 and 5 s, respectively. Drug testing began, after responses of individual subjects were stable (≥50% accuracy with no apparent increasing or decreasing trend for at least five sessions).
d-Amphetamine sulfate (obtained from Sigma Aldrich, St. Louis, Missouri, USA) was dissolved in 0.9% saline (NaCl) and injected intraperitoneally at a volume of 1 ml/ kg body weight. Doses (0.1, 0.3, 1.0, and 1.7 mg/kg) are expressed in terms of the salt and were typically tested twice in each subject on Tuesdays and Fridays. In addition, doses of d-amphetamine were administered in a pseudo-random order at each of the following time points before testing: 5, 15, 30, 5, 60, 120, and 240 min. All doses were tested at a given time point before moving to the next. Performances at the two 5-min time point determinations were not statistically different and were therefore averaged for the final analysis.
Amphetamine plasma levels
Plasma levels of d-amphetamine were determined in a separate group of subjects. Blood was sampled at 15, 30, 60, 120, 240, and 360 min after intraperitoneal administration of 1.0 mg/kg d-amphetamine (a dose that resulted in the most consistent increases in percent correct relative to control values across the various administration times). At each time point,~0.2 ml of blood was collected by retro-orbital bleeding. Blood samples were dispensed into 2-ml Vacutainer hematology tubes, containing 4 mg of K3 ethylenediaminetetraacetic acid solution (BectonDickinson, Franklin Lakes, New Jersey, USA), and stored on ice for up to 30 min, until centrifuged. Samples were centrifuged at 1100g for 10 min (Sorvall RC2-B; Kendro Laboratory Products, Newtown, Connecticut, USA). Plasma was withdrawn using a 5-ml 3/4 Pasteur pipette and decanted into 1.5-ml polypropylene tubes. Sodium metabisulfite (250 mmol/l) was added at a volume of 30 µl/ml plasma to minimize compound oxidation. Samples were stored at − 20°C until assayed.
Plasma aliquots (100 µl) were preserved with 20 µl of sodium metabisulfite (250 mmol/l) and 10 µl of EDTA (250 mmol/l). After addition of 100 µl of the internal standard solution (d 8 -amphetamine, 1000 ng/ml), each sample was briefly mixed. Ten µl of perchloric acid was added and samples vortexed to perform protein precipitation. Subsequently, samples were centrifuged (13 000g for 5 min) and 10 µl of the supernatant was injected into a liquid chromatographic/mass spectrometric. All samples were analyzed using an AT series 1100 LC/MSD, VL version (Agilent Technologies, Waldbronn, Germany), using electron spray ionization in positive ionization mode, including an AT 1100 series HPLC system that consisted of a degasser, a quaternary pump, a column thermostat, and an autosampler. Isocratic elution was performed on a Zorbax 300-SCX column (Narrow-Bore 2.1 × 150 mm, 5 µm). The mobile phase consisted of 5 mmol/l aqueous ammonium formate adjusted to pH 3 with formic acid (eluent A) and acetonitrile (eluent B). Samples were analyzed in positively selected ion monitoring mode with the following ions: m/z 136 (target ion), 119 for d-amphetamine and 144 (target ion), 127 for d 8 -amphetamine (internal standard). Fragmentor voltage was 100 V. The linear range for each analyte was 10-500 ng/ml d-amphetamine. The lowest point of the calibration curve was defined as the limit of quantification of the method (10 ng/ml d-amphetamine). Quantification of amphetamine was determined by comparison of its peak area ratio (analyte vs. internal standard) to calibration curves in which the peak area ratios of spiked calibrators had been plotted versus their concentration.
Statistical analysis
The percentage of correct 5-CSRT responses was calculated as the total correct responses/total correct plus incorrect multiplied by 100. Response latency was determined as the time from sample stimulus onset to response, ITI responses were recorded as the number of responses during the intertrial interval, and trial omissions were the number of trials without a response. A two-way repeated-measures analysis of variance compared the various determinations of d-amphetamine using within-subject factors of testing time and dose. Multiple-comparison corrected tests were conducted using Bonferroni corrections. Significant differences for all analyses were based upon P less than 0.05. To conduct a repeated-measures analysis of variance, a maximum likelihood estimator (the expectation-maximization algorithm) in SPSS 18 (IBM, Chicago, Illinois, USA) was used to estimate the performance for one subject at 1.7 mg/kg damphetamine (only at the 15-min testing period), because this subject omitted all trials during the respective test session.
The pharmacokinetic parameters consisting of peak plasma concentrations (C max ), half-life (T 1/2 ), time of maximum plasma concentration (T max ), and area under the concentration-time curve for d-amphetamine were calculated using the pharmacokinetic functions for Microsoft Excel. Area under the concentration-time curve was calculated using the linear trapezoidal rule starting at time zero and finishing at the last quantifiable point.
Results
Low doses of d-amphetamine (0.1-0.3 mg/kg) had a relatively little effect on any dependent measure, whereas 1.0 mg/kg d-amphetamine increased percent correct (Fig. 1a, circles) across a range of d-amphetamine administration times. A significant interaction was observed (F 20,100 = 7.75; P < 0.001) with 1.0 mg/kg damphetamine significantly increasing percent correct 30, 60, and 120 min after d-amphetamine administration (P < 0.05). In addition, 1.7 mg/kg d-amphetamine significantly increased percent correct 60 and 120 min after drug administration. However, 15 and 30 min after damphetamine administration the percentage of the correct responses was significantly decreased (P < 0.05). Corresponding time-dependent effects of 1.7 mg/kg damphetamine were observed for trial omissions (Fig. 1b) and response latencies (Fig. 1c) . The dose of 1.7 mg/kg damphetamine significantly increased trial omissions (F 20,100 = 5.70; P < 0.001), but only at 5, 15, and 30 min after injection (P < 0.05) and significantly increased response latency (F 20,100 = 11.59; P < 0.001) at 15 and 30 min after injection (P < 0.05). Thus, at time points when 1.7 mg/kg d-amphetamine decreased percent correct, other measures of performance were also impaired. However, when the 1.7 mg/kg dose increased percent correct, trial omissions and response latencies were not affected. Finally, no statistically significant changes in ITI responses (Fig. 1d) were observed at any dose of damphetamine across all times after injection.
Maximal drug-plasma concentrations after 1.0 mg/kg damphetamine occurred at the earliest time point assessed (15 min) and steadily declined thereafter (Fig. 2a) . A hysteresis plot (Fig. 2b) shows the relation between drug plasma levels after administration of 1.0 mg/kg d-amphetamine and the effects on percent correct during the 5-CSRT assessment. Drug plasma levels that corresponded to a significant increase in percent correct ranged from~44.20 ( 6.87) to 102.14 ( 10.76) ng/ml. Increases in the percentage of correct responses were no longer evident at about 4 h after administration with a d-amphetamine plasma concentration of~11.92 ( 3.97) ng/ml.
Discussion
ADHD is a common disorder among children and is frequently being diagnosed as persisting into adulthood (Biederman et al., 2012) . Amphetamine is widely used to alleviate core ADHD symptoms and new amphetaminebased treatments are being investigated (Childress and Tran, 2016) . The current preclinical experiment sought to determine the relationship of 'therapeutically' active plasma concentrations observed in humans and rodentswith results indicating overlap between plasma concentrations associated with improved performance in both species.
In preclinical studies that model psychostimulant treatment, some investigators have simulated the drug plasma levels observed with the clinical treatment of ADHD symptoms in laboratory animals using both methylphenidate (Kuczenski and Segal, 2002; Berridge et al., 2006; LeBlanc-Duchin and Taukulis, 2007; Rodriguez et (Ricaurte et al., 2005; Soto et al., 2012) . However, it is less common to demonstrate that those similar drug plasma levels are also 'therapeutic' in laboratory animals (i.e. the stimulants were also demonstrated to enhance attention or decrease locomotor activity). It appears that only the studies by Kuczenski and Segal (2002) and Berridge et al. (2006) showed that doses of methylphenidate that approximated drug plasma concentrations in the range seen clinically could result in an overall 'therapeutic' change in behavior (e.g. reduction in crossovers in activity chambers as a measure of activity or enhancement in stimulus detection in a sustained attention task, respectively). Kuczenski and Segal (2002) estimated appropriate doses based on previous studies, whereas Berridge et al. (2006) actually determined the relationship between dose and drug plasma concentration.
The current study is the first to show the comprehensive relation between the plasma levels and pharmacodynamics of amphetamine in the 5-CSRT procedure, which has been used as a model of attention in laboratory animals (Robbins, 2002) . Drug effects were assessed over an extended time frame using techniques similar to those employed in clinical studies (Brown et al., 1979 (Brown et al., , 1980 Greenhill et al., 2003) . A wide range (44-102 ng/ml) of d-amphetamine plasma levels obtained after acute 1.0 mg/kg administration corresponded to significant enhancements in percent correct responses. The drug plasma levels obtained in rats overlapped with the wide range reported clinically after oral d-amphetamine dosing in hyperactive children (22.7-65.9 ng/ml), a range sufficient to reduce ADHD-related problem behavior (Brown et al., 1979 (Brown et al., , 1980 . Greenhill et al. (2003) examined the effects of Adderall, Shire-Richwood Inc., Florence, KY (3 : 1, d:l amphetamine) either once or twice daily in ADHD-diagnosed children and found that concentrations of 20-28 or 20-52 ng/ml of d-amphetamine, were associated with therapeutic effects. However, the maximum drug plasma concentrations that enhanced performance in the current study were higher than those reported in the clinical literature, suggesting that concentrations higher than those reported clinically may also be therapeutic (although doserelated toxicity would be an obvious concern). One pharmacological feature not assessed in the current study is the potential for acute tolerance. That is, the same drug plasma concentrations that initially produced a therapeutic effect may no longer produce one. Acute tolerance has been reported in clinical studies at 4 h after administration of a single oral immediate-release damphetamine dose (Brown et al., 1979 (Brown et al., , 1980 Greenhill et al., 2003) . As shown in the hysteresis plot, intraperitoneal administration of 1.0 mg/kg d-amphetamine resulted in plasma levels that decreased substantially between test times and still resulted in enhanced performance up to the 240-min test time. The absence of acute tolerance obtained in this study may be related to the intraperitoneal route of drug administration that differs from the oral route used in clinical studies. With intraperitoneal administration, drug plasma levels likely decrease at a greater rate than would be seen with oral administration. Future studies modeling amphetamine treatment might benefit from the use of the more clinically-relevant oral route of administration, increasing the translational potential.
The enhancement of percent correct responses with 1.0 mg/kg d-amphetamine was relatively sustained across an~1.5-h time frame. However, effects of 1.7 mg/kg damphetamine showed a different profile, with earlier time points (i.e. those before 30 min postadministration) leading to impaired performance, and those after 60 min postadministration leading to improved performance. This likely reflects the fact that plasma levels shortly after administration produced behavioral disruption (evidenced by increased response latencies and trial omissions) that may have interfered with possible 'therapeutic' effects. In contrast, 60 min after administration, 1.7 mg/kg d-amphetamine likely produced plasma levels within a range similar to those produced by administration of 1.0 mg/kg d-amphetamine that enhanced percent correct and did not produce behavioral disruption. A temporary negative effect due to increased plasma concentrations has also been suggested to occur in the clinical population (Swanson and Volkow, 2002) . For example, pediatric ADHD patients treated with 10-20 mg of Adderall showed a decrease in the number of math problems attempted and completed correctly during the first 45 min after treatment (Swanson et al., 1998) . This effect was not observed after treatment with 5 mg of Adderall. At the 1.5-h post-treatment time point, however, optimal 'therapeutic' effects were found following a 15-mg dose. Similarly, following a dose of 20 mg, maximal 'therapeutic' effects occurred 3 h after treatment (see Swanson and Volkow, 2002 for a further discussion of negative effects of certain plasma concentrations). Thus, the pharmacokinetics of d-amphetamine and its effects on behavior in the present study appear to correlate with most clinical observations and support the predictive validity for the present version of the 5-CSRT procedure as a preclinical model that could be useful in assessing novel ADHD therapeutics.
